Wells Fargo & Company Scynexis Inc Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
1 transactions
Others Institutions Holding SCYX
# of Institutions
53Shares Held
14.4MCall Options Held
34KPut Options Held
5K-
Federated Hermes, Inc. Pittsburgh, PA4.21MShares$5.48 Million0.02% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY2.24MShares$2.91 Million0.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.69MShares$2.19 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX1.45MShares$1.88 Million0.14% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC556KShares$722,2210.7% of portfolio
About SCYNEXIS INC
- Ticker SCYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 32,651,800
- Market Cap $42.4M
- Description
- SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...